APO RESEARCH · REPORT
Ischemia Reperfusion Injury
Reperfusion injury or reperfusion insult, sometimes called ischemia-reperfusion injury (IRI) or reoxygenation injury, is the tissue damage caused when blood supply returns to tissue (re- + perfusion) after a period of ischemia or lack of oxygen (anoxia or hypoxia). The absence of oxygen and nutrients from blood during the ischemic period creates a condition in which the restoration of circulation results in inflammation and oxidative damage through the induction of oxidative stress rather than (or along with) restoration of normal function.
Product & engineering
Understand the product.
Reperfusion injury or reperfusion insult, sometimes called ischemia-reperfusion injury (IRI) or reoxygenation injury, is the tissue damage caused when blood supply returns to tissue (re- + perfusion) after a period of ischemia or lack of oxygen (anoxia or hypoxia). The absence of oxygen and nutrients from blood during the ischemic period creates a condition in which the restoration of circulation results in inflammation and oxidative damage through the induction of oxidative stress rather than (or along with) restoration of normal function.
Selected research
Industry Research
Ischemia Reperfusion Injury Industry Research Report 2026
Market perspective
Reperfusion injury or reperfusion insult, sometimes called ischemia-reperfusion injury (IRI) or reoxygenation injury, is the tissue damage caused when blood supply returns to tissue (re- + perfusion) after a period of ischemia or lack of oxygen (anoxia or hypoxia). The absence of oxygen and nutrients from blood during the ischemic period creates a condition in which the restoration of circulation results in inflammation and oxidative damage through the induction of oxidative stress rather than (or along with) restoration of normal function.
Global Ischemia Reperfusion Injury key players include Angion Biomedica, Catalyst Biosciences, Ischemix Inc, etc.
North America is the largest market, with a share about 50%, followed by Europe, and Japan, both have a share over 20 percent.
Read the full market overview
In terms of product, Phase 2 is the largest segment, with a share about 40%. And in terms of application, the largest application is Kidney Injury, followed by Heart Injury, Intestine Injury, etc.
Report Scope
This report quantifies the global Ischemia Reperfusion Injury market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Ischemia Reperfusion Injury.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Ischemia Reperfusion Injury Market by Company
Angion Biomedica
Catalyst Biosciences
Ischemix Inc
Opsona Therapeutics
Pharming
TheraSource
Bolder Biotechnology
Corline Biomedical
Mifcortx
Balmes Transplantation
NovelMed Therapeutics
Hope Pharmaceuticals
Omeros Corp
Prothix
SBI Pharmaceuticals
Ischemia Reperfusion Injury Segment by Type
Phase 1
Phase 2
Preclinical
Ischemia Reperfusion Injury Segment by Application
Heart Injury
Kidney Injury
Intestine Injury
Other Injury
Ischemia Reperfusion Injury Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Ischemia Reperfusion Injury market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Ischemia Reperfusion Injury and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Ischemia Reperfusion Injury.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Ischemia Reperfusion Injury companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Phase 1
- Phase 2
- Preclinical
Applications
- Heart Injury
- Kidney Injury
- Intestine Injury
- Other Injury
Companies covered
- Angion Biomedica
- Catalyst Biosciences
- Ischemix Inc
- Opsona Therapeutics
- Pharming
- TheraSource
- Bolder Biotechnology
- Corline Biomedical
- Mifcortx
- Balmes Transplantation
- NovelMed Therapeutics
- Hope Pharmaceuticals
- Omeros Corp
- Prothix
- SBI Pharmaceuticals
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Ischemia Reperfusion Injury by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Phase 1
- 2.2.3 Phase 2
- 2.2.4 Preclinical
- 2.3 Ischemia Reperfusion Injury by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Heart Injury
- 2.3.3 Kidney Injury
- 2.3.4 Intestine Injury
- 2.3.5 Other Injury
- 2.4 Assumptions and Limitations
3 Ischemia Reperfusion Injury Breakdown Data by Type
- 3.1 Global Ischemia Reperfusion Injury Historic Market Size by Type (2021-2026)
- 3.2 Global Ischemia Reperfusion Injury Forecasted Market Size by Type (2027-2032)
4 Ischemia Reperfusion Injury Breakdown Data by Application
- 4.1 Global Ischemia Reperfusion Injury Historic Market Size by Application (2021-2026)
- 4.2 Global Ischemia Reperfusion Injury Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Ischemia Reperfusion Injury Market Perspective (2021-2032)
- 5.2 Global Ischemia Reperfusion Injury Growth Trends by Region
- 5.2.1 Global Ischemia Reperfusion Injury Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Ischemia Reperfusion Injury Historic Market Size by Region (2021-2026)
- 5.2.3 Ischemia Reperfusion Injury Forecasted Market Size by Region (2027-2032)
- 5.3 Ischemia Reperfusion Injury Market Dynamics
- 5.3.1 Ischemia Reperfusion Injury Industry Trends
- 5.3.2 Ischemia Reperfusion Injury Market Drivers
- 5.3.3 Ischemia Reperfusion Injury Market Challenges
- 5.3.4 Ischemia Reperfusion Injury Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Ischemia Reperfusion Injury Players by Revenue
- 6.1.1 Global Top Ischemia Reperfusion Injury Players by Revenue (2021-2026)
- 6.1.2 Global Ischemia Reperfusion Injury Revenue Market Share by Players (2021-2026)
- 6.2 Global Ischemia Reperfusion Injury Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Ischemia Reperfusion Injury Head Office and Area Served
- 6.4 Global Ischemia Reperfusion Injury Players, Product Type & Application
- 6.5 Global Ischemia Reperfusion Injury Manufacturers Established Date
- 6.6 Global Ischemia Reperfusion Injury Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Ischemia Reperfusion Injury Market Size (2021-2032)
- 7.2 North America Ischemia Reperfusion Injury Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Ischemia Reperfusion Injury Market Size by Country (2021-2026)
- 7.4 North America Ischemia Reperfusion Injury Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Ischemia Reperfusion Injury Market Size (2021-2032)
- 8.2 Europe Ischemia Reperfusion Injury Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Ischemia Reperfusion Injury Market Size by Country (2021-2026)
- 8.4 Europe Ischemia Reperfusion Injury Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Ischemia Reperfusion Injury Market Size (2021-2032)
- 9.2 Asia-Pacific Ischemia Reperfusion Injury Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Ischemia Reperfusion Injury Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Ischemia Reperfusion Injury Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Ischemia Reperfusion Injury Market Size (2021-2032)
- 10.2 South America Ischemia Reperfusion Injury Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Ischemia Reperfusion Injury Market Size by Country (2021-2026)
- 10.4 South America Ischemia Reperfusion Injury Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Ischemia Reperfusion Injury Market Size (2021-2032)
- 11.2 Middle East & Africa Ischemia Reperfusion Injury Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Ischemia Reperfusion Injury Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Ischemia Reperfusion Injury Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Angion Biomedica
- 12.1.1 Angion Biomedica Company Information
- 12.1.2 Angion Biomedica Business Overview
- 12.1.3 Angion Biomedica Revenue in Ischemia Reperfusion Injury Business (2021-2026)
- 12.1.4 Angion Biomedica Ischemia Reperfusion Injury Product Portfolio
- 12.1.5 Angion Biomedica Recent Developments
- 12.2 Catalyst Biosciences
- 12.2.1 Catalyst Biosciences Company Information
- 12.2.2 Catalyst Biosciences Business Overview
- 12.2.3 Catalyst Biosciences Revenue in Ischemia Reperfusion Injury Business (2021-2026)
- 12.2.4 Catalyst Biosciences Ischemia Reperfusion Injury Product Portfolio
- 12.2.5 Catalyst Biosciences Recent Developments
- 12.3 Ischemix Inc
- 12.3.1 Ischemix Inc Company Information
- 12.3.2 Ischemix Inc Business Overview
- 12.3.3 Ischemix Inc Revenue in Ischemia Reperfusion Injury Business (2021-2026)
- 12.3.4 Ischemix Inc Ischemia Reperfusion Injury Product Portfolio
- 12.3.5 Ischemix Inc Recent Developments
- 12.4 Opsona Therapeutics
- 12.4.1 Opsona Therapeutics Company Information
- 12.4.2 Opsona Therapeutics Business Overview
- 12.4.3 Opsona Therapeutics Revenue in Ischemia Reperfusion Injury Business (2021-2026)
- 12.4.4 Opsona Therapeutics Ischemia Reperfusion Injury Product Portfolio
- 12.4.5 Opsona Therapeutics Recent Developments
- 12.5 Pharming
- 12.5.1 Pharming Company Information
- 12.5.2 Pharming Business Overview
- 12.5.3 Pharming Revenue in Ischemia Reperfusion Injury Business (2021-2026)
- 12.5.4 Pharming Ischemia Reperfusion Injury Product Portfolio
- 12.5.5 Pharming Recent Developments
- 12.6 TheraSource
- 12.6.1 TheraSource Company Information
- 12.6.2 TheraSource Business Overview
- 12.6.3 TheraSource Revenue in Ischemia Reperfusion Injury Business (2021-2026)
- 12.6.4 TheraSource Ischemia Reperfusion Injury Product Portfolio
- 12.6.5 TheraSource Recent Developments
- 12.7 Bolder Biotechnology
- 12.7.1 Bolder Biotechnology Company Information
- 12.7.2 Bolder Biotechnology Business Overview
- 12.7.3 Bolder Biotechnology Revenue in Ischemia Reperfusion Injury Business (2021-2026)
- 12.7.4 Bolder Biotechnology Ischemia Reperfusion Injury Product Portfolio
- 12.7.5 Bolder Biotechnology Recent Developments
- 12.8 Corline Biomedical
- 12.8.1 Corline Biomedical Company Information
- 12.8.2 Corline Biomedical Business Overview
- 12.8.3 Corline Biomedical Revenue in Ischemia Reperfusion Injury Business (2021-2026)
- 12.8.4 Corline Biomedical Ischemia Reperfusion Injury Product Portfolio
- 12.8.5 Corline Biomedical Recent Developments
- 12.9 Mifcortx
- 12.9.1 Mifcortx Company Information
- 12.9.2 Mifcortx Business Overview
- 12.9.3 Mifcortx Revenue in Ischemia Reperfusion Injury Business (2021-2026)
- 12.9.4 Mifcortx Ischemia Reperfusion Injury Product Portfolio
- 12.9.5 Mifcortx Recent Developments
- 12.10 Balmes Transplantation
- 12.10.1 Balmes Transplantation Company Information
- 12.10.2 Balmes Transplantation Business Overview
- 12.10.3 Balmes Transplantation Revenue in Ischemia Reperfusion Injury Business (2021-2026)
- 12.10.4 Balmes Transplantation Ischemia Reperfusion Injury Product Portfolio
- 12.10.5 Balmes Transplantation Recent Developments
- 12.11 NovelMed Therapeutics
- 12.11.1 NovelMed Therapeutics Company Information
- 12.11.2 NovelMed Therapeutics Business Overview
- 12.11.3 NovelMed Therapeutics Revenue in Ischemia Reperfusion Injury Business (2021-2026)
- 12.11.4 NovelMed Therapeutics Ischemia Reperfusion Injury Product Portfolio
- 12.11.5 NovelMed Therapeutics Recent Developments
- 12.12 Hope Pharmaceuticals
- 12.12.1 Hope Pharmaceuticals Company Information
- 12.12.2 Hope Pharmaceuticals Business Overview
- 12.12.3 Hope Pharmaceuticals Revenue in Ischemia Reperfusion Injury Business (2021-2026)
- 12.12.4 Hope Pharmaceuticals Ischemia Reperfusion Injury Product Portfolio
- 12.12.5 Hope Pharmaceuticals Recent Developments
- 12.13 Omeros Corp
- 12.13.1 Omeros Corp Company Information
- 12.13.2 Omeros Corp Business Overview
- 12.13.3 Omeros Corp Revenue in Ischemia Reperfusion Injury Business (2021-2026)
- 12.13.4 Omeros Corp Ischemia Reperfusion Injury Product Portfolio
- 12.13.5 Omeros Corp Recent Developments
- 12.14 Prothix
- 12.14.1 Prothix Company Information
- 12.14.2 Prothix Business Overview
- 12.14.3 Prothix Revenue in Ischemia Reperfusion Injury Business (2021-2026)
- 12.14.4 Prothix Ischemia Reperfusion Injury Product Portfolio
- 12.14.5 Prothix Recent Developments
- 12.15 SBI Pharmaceuticals
- 12.15.1 SBI Pharmaceuticals Company Information
- 12.15.2 SBI Pharmaceuticals Business Overview
- 12.15.3 SBI Pharmaceuticals Revenue in Ischemia Reperfusion Injury Business (2021-2026)
- 12.15.4 SBI Pharmaceuticals Ischemia Reperfusion Injury Product Portfolio
- 12.15.5 SBI Pharmaceuticals Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst